Jump to content

Nialamide: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)
consistent citation formatting
Line 38: Line 38:
}}
}}


'''Nialamide''' ('''Niamid''', '''Niamide''', '''Nuredal''', '''Surgex''') is a non-selective, [[irreversible inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class that was used as an [[antidepressant]].<ref name="Publishing2006">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935|date=1 December 2006|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref> It was withdrawn by [[Pfizer]] several decades ago due to the risk of [[hepatotoxicity]].<ref name="Gad2012">{{cite book|author=Shayne C. Gad|title=Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition|url=https://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138|date=26 April 2012|publisher=CRC Press|isbn=978-1-4398-4567-7|pages=138–}}</ref><ref name="Shorter2008">{{cite book|author=Edward Shorter|title=Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry|url=https://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137|date=28 September 2008|publisher=Oxford University Press|isbn=978-0-19-970933-5|pages=137–}}</ref>
'''Nialamide''' ('''Niamid''', '''Niamide''', '''Nuredal''', '''Surgex''') is a non-selective, [[irreversible inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class that was used as an [[antidepressant]].<ref name="Publishing2006">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia | edition = 3rd | url = https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935|date=1 December 2006|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref> It was withdrawn by [[Pfizer]] several decades ago due to the risk of [[hepatotoxicity]].<ref name="Gad2012">{{cite book| vauthors = Gad SC |title=Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition|url=https://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138|date=26 April 2012|publisher=CRC Press|isbn=978-1-4398-4567-7|pages=138–}}</ref><ref name="Shorter2008">{{cite book| first = Edward | last = Shorter | name-list-format = vanc |title=Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry|url=https://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137|date=28 September 2008|publisher=Oxford University Press|isbn=978-0-19-970933-5|pages=137–}}</ref>


The antiatherogenic activity of nialamide was used to design [[pyridinolcarbamate]].<ref>{{cite web|url=https://books.google.co.uk/books?id=a1bmCAAAQBAJ&pg=PA387#v=onepage&q&f=false|title=Hypolipidemic Agents|first1=W. L.|last1=Bencze|first2=M. E.|last2=Dempsey|first3=S.|last3=Eisenberg|first4=J. M.|last4=Felts|first5=I. D.|last5=Frantz|first6=R.|last6=Hess|first7=R. I.|last7=Levy|first8=T. A.|last8=Miettinen|first9=L. L.|last9=Rudel|first10=H. S.|last10=Sodhi|first11=W.|last11=Stäubli|first12=T.|last12=Zemplényi|date=6 December 2012|publisher=Springer Science & Business Media|accessdate=3 October 2017|via=Google Books}}</ref>
The antiatherogenic activity of nialamide was used to design [[pyridinolcarbamate]].<ref>{{cite journal | vauthors = Bencze WL, Hess R, DeStevens G | title = Hypolipidemic agents | journal = Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques | volume = 13 | pages = 217–92 | date = 6 December 2012 | pmid = 4982663 | doi = 10.1007/978-3-0348-7068-9_5 | url = https://books.google.com/books?id=a1bmCAAAQBAJ&pg=PA387#v=onepage | access-date = 3 October 2017 | publisher = Springer Science & Business Media | isbn = 9783642661907 }}</ref>


==See also==
== See also ==
* [[Hydrazine (antidepressant)]]
* [[Hydrazine (antidepressant)]]


==References==
== References ==
{{Reflist|2}}
{{Reflist|2}}


Revision as of 17:36, 27 August 2020

Nialamide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Identifiers
  • N-benzyl-3-(N-(pyridine-4-carbonyl)hydrazino)propanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.000.073 Edit this at Wikidata
Chemical and physical data
FormulaC16H18N4O2
Molar mass298.346 g·mol−1
3D model (JSmol)
  • O=C(NNCCC(=O)NCc1ccccc1)c2ccncc2
  • InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) checkY
  • Key:NOIIUHRQUVNIDD-UHFFFAOYSA-N checkY
  (verify)

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]

The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[4]

See also

References

  1. ^ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  2. ^ Gad SC (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
  3. ^ Shorter, Edward (28 September 2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5. {{cite book}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  4. ^ Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic agents". Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques. 13. Springer Science & Business Media: 217–92. doi:10.1007/978-3-0348-7068-9_5. ISBN 9783642661907. PMID 4982663. Retrieved 3 October 2017.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nialamide&oldid=975265002"